SoFi Invest
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
9 Meters Biopharma is a business based in the US. 9 Meters Biopharma shares (INNT) are listed on the NASDAQ and all prices are listed in US Dollars. 9 Meters Biopharma employs 8 staff and has a market cap (total outstanding shares value) of 0.00.
SoFi Invest
eToro
tastytrade
52-week range | $0.00 - $0.00 |
---|---|
50-day moving average | $0.73 |
200-day moving average | $0.61 |
Wall St. target price | $10.00 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-0.49 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Gross profit TTM | $0 |
---|---|
Return on assets TTM | -193.21% |
Return on equity TTM | 0% |
Profit margin | 0% |
Book value | $0.14 |
Market capitalisation | $23.1 million |
TTM: trailing 12 months
We're not expecting 9 Meters Biopharma to pay a dividend over the next 12 months.
9 Meters Biopharma's shares were split on a 1:10 basis on 1 February 2018. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your 9 Meters Biopharma shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for 9 Meters Biopharma shares which in turn could have impacted 9 Meters Biopharma's share price.
Over the last 12 months, 9 Meters Biopharma's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while 9 Meters Biopharma's is -0.5435. This would suggest that 9 Meters Biopharma's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, 9 Meters Biopharma has bucked the trend.
9 Meters Biopharma, Inc. operates as a rare, orphan, and unmet needs-focused GI company. The company is advancing its drug candidates for short bowel syndrome and celiac disease. Its product candidates include NM-002, a proprietary long-acting GLP-1 agonist into Phase 2 trial for short bowel syndrome; and larazotide, a Phase 3 tight junction regulator being evaluated for patient-reported symptom improvement in non-responsive celiac disease. The company's pipeline products also includes NM-004, an oral gut restricted immunomodulator and NM-003, a long-acting GLP-2 analogue, both of which are under orphan indication selection. 9 Meters Biopharma, Inc. owns global rights to its products.
Here’s what happens to your securities if your brokerage fails, and how your assets are protected by SIPC and FDIC.
Learn about buying physical gold, plus stocks and ETFs, to learn how you can add gold exposure to your portfolio.
Several ETFs have exposure to Silicon Valley Bank, but it appears minimal.
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
The 16th largest US bank has collapsed, but its impact on your portfolio could be limited depending on what you own.
Steps to investing in the Vanguard (VTI) Total Stock Market ETF.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.